|| List of recent Proteins-related patents
|Method for increasing or decreasing the development of sylleptic or proleptic branching in a ligneous plant|
A biotechnological application of the rav1 gene (related to abi3 and viviparous 1) and its homologue rav2 in relation to their capacity to increase or reduce the development of sylleptic and/or proleptic branches in ligneous species when their expression levels or the activity of the proteins they encode are modified. It is possible to increase the biomass production of a ligneous species plantation or to reduce the number of nodes in the trunk of ligneous species of logging interest by means of modifying the expression of said genes..
|Hppd variants and methods of use|
The present invention relates to an isolated nucleic acid comprising a nucleotide sequence encoding a mutated hppd protein, wherein said mutated hppd protein has hppd activity, wherein in said mutated hppd protein at least one amino acid has been replaced so that the resulting amino acid sequence comprises at least one amino acid selected from certain amino acids at specific positions important for conferring an increased hppd inhibitor tolerance. The present invention also relates to proteins encoded by the nucleic acid of the invention, to chimeric genes, plant cells comprising the nucleic acid of the invention operably linked to a plant-expressible promoter and optionally a transcription termination and polyadenylation region, plants essentially consisting of the plant cells of the invention and methods of obtaining transgenic plants..
|Systems and methods for predicting protein-ligand interactions|
Systems and methods for predicting protein-ligand interactions are disclosed. An exemplary method can include identifying a set of structural neighbours of the query proteins, where each of contains ligands.
|Multi-functional hybrid devices/structures using 3d printing|
A bioelectronic device and method of making is disclosed. The device includes a scaffold formed via 3d printing.
|Method for immobilizing membrane proteins on surfaces|
Disclosed herein are methods for immobilizing membrane proteins or membrane protein complexes on analytical surfaces, which in some aspects comprise: obtaining a membrane protein or membrane protein complex comprising a capture moiety; immobilizing the membrane protein or membrane protein complex on the analytical surface by means of the capture moiety; and stabilizing at least one of the secondary, tertiary, or quaternary structures of the immobilized membrane protein or membrane protein complex by crosslinking with a crosslinking reagent. Also disclosed are analytical surfaces, which in some aspects comprise: a membrane protein or membrane protein complex comprising a capture moiety, wherein the membrane protein or membrane protein complex is immobilized on the analytical surface by means of the capture moiety, and wherein at least one of the secondary, tertiary, or quaternary structures of the membrane protein or membrane protein complex is stabilized by crosslinking..
|Method for synthesizing proteins|
Method for assembling proteins from peptide fragments. It allows the production of proteins in a manner that is simple, reliable and applicable on an industrial scale.
|Dual-aav vector-based systems and methods for delivering oversized genes to mammalian cells|
Disclosed are materials and methods for treating diseases of the mammalian eye, and in particular, usher syndrome 1b (ush1b). The invention provides aav-based, dual-vector systems that facilitate the expression of full-length proteins whose coding sequences exceed that of the polynucleotide packaging capacity of an individual aav vector.
|In vitro and in vivo delivery of genes and proteins using the bacteriophage t4 dna packaging machine|
Described is t4 dna packaging machine comprising: one or more dna molecules packaged in a head of the t4 dna packaging machine, one or more hoc-fused proteins displayed on the head of the t4 dna packaging machine, and one or more soc-fused proteins displayed on the head of the t4 dna packaging machine. Also described are methods of making and using such a t4 dna packaging machine..
|Methods for identifying and compounds useful for increasing the functional activity and cell surface expression of cf-associated mutant cystic fibrosis transmembrance conductance regulator|
The present invention relates to agents, and methods for identifying compounds, which agents and compounds result in the modulation of cellular trafficking of proteins in particular that of cf-associated mutant cystic fibrosis transmembrane conductance regulator (cftr). In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by an er-associated protein misfolding and abnormal cellular trafficking of disease-associated proteins, including cystic fibrosis (cf)..
|Opsin-binding ligands, compositions and methods of use|
Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic is visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions.
|Heterocyclic molecules as apoptosis inducers|
The present document describes novel compounds which may inhibit the activity of anti-apoptotic proteins such as bcl-2 family protein members, compositions containing the compounds and methods of treating diseases involving a defect in apoptosis, such as, for example, in the treatment of cancer.. .
|Relaxin proteins for use in the diagnosis, prevention or treatment of multiple sclerosis|
The present invention relates to the use of one or more relaxin proteins in methods for diagnoses and treatment of multiple sclerosis. The invention also provides compositions for use in diagnosing or treating multiple sclerosis as well as the methods themselves.
Protein arrays are provided comprising single domain antibodies obtainable from camelidae which are capable of detecting even minor changes in the expression of proteins in cell and tissue extracts and having an optimal signal to noise ratio by removing non-informative abundant proteins from said cell or tissue extracts.. .
|Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof|
The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection..
|Ph-insensitive glucose indicator protein|
The present invention encompasses a glucose indicator protein, a biosensor comprising one or more glucose indicator proteins, and methods of use thereof.. .
The invention relates to recombinantly produced β-glucosidase variants with enhanced thermoactivity compared to naturally occurring proteins. The invention also provides methods for producing a variant β-glucosidase polypeptide with improved thermoactivity by identifying performance sensitive positions in a target β-glucosidase polypeptide and substituting the residue at that position with a thermoactivity enhancing residue..
|Saccharide-containing protein conjugates and uses thereof|
Conjugates of a saccharide and a biomolecule, covalently linked therebetween via a non-hydrophobic linker and methods of preparing same are disclosed. Also disclosed are medical uses utilizing such conjugates.
|Overexpression of aminoacyl-trna synthetases for efficient production of engineered proteins containing amino acid analogues|
Methods for producing modified polypeptides containing amino acid analogues are disclosed. The invention further provides purified dihydrofolate reductase polypeptides, produced by the methods of the invention, in which the methionine residues have been replaced with homoallylglycine, homoproparglycine, norvaline, norleucine, cis-crotylglycine, trans-crotylglycine, 2-aminoheptanoic acid, 2-butynylglycine and allylglycine..
|Production of glycoproteins with low n-glycolylneuraminic acid (neu5gc) content|
The present invention relates to a medium for the cultivation of eukaryotic cells, the medium comprising as (an) additive(s) dmso, n-acetylmannosamine (nacman), n-acetylglucosamine (nacglc), or any combination of two or more of these additives, including the combination of nacman and nacglc.. .
|Prokaryote-based cell-free system for the synthesis of glycoproteins|
The present invention is directed to a cell-free system for producing a glycosylated protein. This system comprises an isolated oligosaccharyltransferase capable of transferring a glycan from a lipid carrier molecule to a glycoprotein target, one or more isolated glycans, where each glycan is linked to a lipid carrier molecule, and a glycoprotein target comprising one or more glycan acceptor amino acid residues or a nucleic acid molecule encoding said glycoprotein target.
|Rna splicing alterations and u1 small nuclear ribonucleoproteins in neurodegenerative diseases|
This disclosure relates to methods of diagnosing neurodegenerative disease by analyzing proteins or protein expression profiles in a subject, or rna or rna expression profiles in a subject. In certain embodiments, the disclosure contemplates the diagnosis of preclinical or symptomatic stages of alzheimer's disease, mild cognitive impairment, or chronic traumatic encephalopathy by identification of components of u1 small nuclear ribonucleoproteins or fragments thereof which are capable of forming cytoplasmic tangle-like structures..
|Method for coating substrates with at least one monolayer of self-assembling proteins|
The invention relates to methods for coating a substrate with at least one monolayer of self-assembling proteins, using stabilized aqueous solutions with self-assembling proteins, and also to substrates obtainable as a result. Methods for stabilizing solutions with self-assembling proteins, and the stabilized solutions obtainable therefrom, are likewise provided by the invention.
|Nutritional compositions containing an enriched lipid fraction and uses thereof|
The present disclosure relates to a nutritional composition comprising a fat source that includes an enriched lipid fraction derived from milk. The enriched lipid fraction may contain saturated fatty acids, trans-fatty acids, monounsaturated fatty acids, clas, bcfas, cholesterol, milk fat globule membrane proteins, gangliosides, and mixtures thereof.
|Enhancement of the efficacy of therapeutic proteins|
A formulation for administration of at least one therapeutic mammalian protein to a mammal or a protein selected from the group, and for enhancing the absorption, distribution and release of the at least one therapeutic mammalian protein in or on the mammal, comprising at least one therapeutic mammalian protein in a micro-emulsion comprising a dispersion of vesicles or microsponges of a fatty acid based component in an aqueous or other pharmacologically acceptable carrier in which nitrous oxide is dissolved, the fatty acid based component comprising at least one long chain fatty acid based substance selected from the group consisting of free fatty acids and derivatives of free fatty acids. A method for effective delivery of at least one therapeutic mammalian protein to a mammal and for enhancing the therapeutic efficacy of such at least one therapeutic mammalian protein, comprising the step of administering the at least one therapeutic mammalian protein to the mammal in such a formulation..
|Methods of wound care and treatment|
Provided are electrokinetically-altered fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating a wound to a surface tissue or a symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents.
|Peptides derived from camplobacter jejuni and their use in vaccination|
Disclosed are polypeptides for campylobacter jejuni that are useful as immungenic agents for vaccine use. Also disclosed are nucleic acid fragments encoding the polypeptides as well as compositions, methods and molecular biology tools derived from or related to the proteins..
|Recombinant human naglu protein and uses thereof|
The present invention provides compositions comprising an isolated mixture of recombinant human naglu proteins in which a substantial amount of the naglu proteins in the mixture has increased levels of phosphorylated mannose that confer the proteins to be efficiently internalized into human cells. The present invention also provides methods of producing such mixture of naglu proteins, vectors used in transgenesis and expression, host cells harboring such vectors, and methods of isolating and purifying the mixture of naglu proteins.
|Stabilized compositions against ionising radiation|
This invention relates to improvements to medical devices such as biosensors containing proteins such as oxidoreductases, for example oxidase and/or peroxidase enzymes. More generally it relates to novel compositions containing proteins which are stabilised to ionising radiation..
|Pharmaceutical composition comprising albumin-binding arginine deiminase for cancer targeting treatment|
The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase fusion protein (aad) for treating cancer or other arginine-dependent diseases. The aad fusion protein can be purified from both soluble and insoluble fractions of crude proteins, it binds to human serum albumin (hsa) and has its high activity with longer half life for efficient depletion of arginine in cancer cells.
Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis.
|Antibodies against tl1a and uses thereof|
The disclosure provides tnf-like ligand 1a (tl1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to tl1a and inhibits interaction of tl1a and death receptor 3 (dr3) and which does not inhibit the interaction of tl1a and decoy receptor 3 (dcr3). The disclosure also provides uses of the tl1a-binding proteins..
|Method and system for selective isolation of target biological molecules in a general purpose system|
Embodiments of the present techniques provide systems and methods for isolating particular classes of biological molecules, for example, proteins or nucleic acids, from mixtures of biological components. The methods use solutions that react with the biological molecules to enhance their adsorption by substrates, allowing contaminants to be washed away from the targeted molecules.
|Dissolvable bed chromatographic column and methods of use|
An automated or semi-automated method was developed for the isolation of proteins using lanthanide metals. Phosphoproteins and glycoproteins can be isolated from complex biological samples using filtration with novel column configurations..
|Apparatus for preparing nucleic acids and method for preparing nucleic acids|
An apparatus for preparing nucleic acids is provided which includes an anode, a cathode, and a space formed between the anode and the cathode. In addition, in the apparatus described above, the space includes a first porous film provided at an anode side, a second porous film provided at a cathode side, an inlet port which is proved in a region sandwiched between the first porous film and the second porous film and which introduces a specimen containing proteins and nucleic acids into the region, and a gel filter provided between the inlet port and the first porous film..
|Acetyl co-enzyme a carboxylase herbicide resistant plants|
The present invention provides for compositions and methods for producing crop plants that are resistant to herbicides. In particular, the present invention provides for wheat plants, plant tissues and plant seeds that contain altered acetyl-coa carboxylase (accase) genes and proteins that are resistant to inhibition by herbicides that normally inhibit the activity of the accase protein..
|Methods for making and using molecular switches involving circular permutation|
The invention provides molecular switches which couple external signals to functionality, and combinatorial methods of making and using the same involving circular permutation of nucleic acid and amino acid sequences. The switches according to the invention can be used, for example, to regulate gene transcription, target drug delivery to specific cells, transport drugs intracellularly, control drug release, provide conditionally active proteins, perform metabolic engineering, and modulate cell signaling pathways.
|Using sortases to install click chemistry handles for protein ligation|
Methods and reagents for the installation of click chemistry handles on target proteins are provided, as well as modified proteins comprising click chemistry handles. Further, chimeric proteins, for example, bi-specific antibodies, that comprise two proteins conjugated via click chemistry, as well as methods for their generation and use are disclosed herein..
|Compositions and methods for transient expression of recombinant rna|
Compositions for transient but prolonged exogenous mrna expression through the use of the transcription system of negative strand rna viruses, and methods of use thereof are disclosed. In some embodiments, the system contains only rnas and does not include any dna molecules.
|Protein synthesis required for long-term memory is induced by pkc activation on days preceding associative learning|
The present invention provides methods of contacting a protein kinase c (pkc) activator with a pkc activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase c (pkc) activator with a pkc activator in a manner sufficient to downregulate pkc..
|Enhanced anabolic cytokine production and delivery system|
Techniques and devices for removing (filtering out) unwanted/inhibitory components (for example, products, byproducts and/or cell output such as inhibitory catabolic proteins) from a composition (for example, autologous fluid or serum) containing such unwanted/inhibitory components. The devices include at least one construct designed to contain a composition (for example, autologous fluid or serum) containing inhibitory/unwanted components (products, byproducts and/or output of cells such as inhibitory catabolic proteins).
|Novel glyphosate-n-acetyltransferase (gat) genes|
Novel proteins are provided herein, including proteins capable of catalyzing the acetylation of glyphosate and other structurally related proteins. Also provided are novel polynucleotides capable of encoding these proteins, compositions that include one or more of these novel proteins and/or polynucleotides, recombinant cells and transgenic plants comprising these novel compounds, diversification methods involving the novel compounds, and methods of using the compounds.
|Methods for enhancing the degradation of cellulosic material with chitin binding proteins|
The present invention relates to methods for degrading or converting a cellulosic material and for producing substances from the cellulosic material.. .
|Enhancing spinosyn production with oxygen binding proteins|
The invention describes the integration of polynucleotides into chromosomal dna of s. Spinosa species, which are useful for the production of insecticides, integrants thereof, and also to the use of the integrants.
|Assay for histidinyl hydroxylase activity|
The present invention relates to assays for monitoring activity of mina53 and no66 activities, in particular, to assays for identifying modulators of mina53 and no66 activities. The invention also relates to assays to monitor the histidinyl hydroxylase activity of mina53 and no66 on their substrates, the human ribosomal protein rpl27a and rpl8 respectively.
|Microfluidic devices and methods for cell sorting, cell culture and cells based diagnostics and therapeutics|
Microfluidic devices and methods that use cells such as cancer cells, stem cells, blood cells for preprocessing, sorting for various biodiagnostics or therapeutical applications are described. Microfluidics electrical sensing such as measurement of field potential or current and phenomena such as immiscible fluidics, inertial fluidics are used as the basis for cell and molecular processing (e.g., characterizing, sorting, isolation, processing, amplification) of different particles, chemical compositions or biospecies (e.g., different cells, cells containing different substances, different particles, different biochemical compositions, proteins, enzymes etc.).
|Quantification of vaccine compositions|
The invention provides methods and mass-labeled peptides for use in said methods for quantifying the presence of a one or more viral proteins in a sample of a preparation containing agents which bind to said viral protein, using mass-spectroscopic analyses of the sample and standards containing known amounts of labeled and unlabeled signature peptides, in particular wherein said viral proteins are antigens in a vaccine for porcine circovirus.. .
|Enhanced performance hydrogen peroxide formulations comprising proteins and surfactants|
Disclosed herein are compositions comprising: an oxidizing agent; a surfactant; and a protein component. Also disclosed are methods of cleaning a surface, the method comprising applying an aqueous solution to the surface, the solution comprising the above compositions..
|Divalent-metal coated nanoparticles for delivery of compositions into the central nervous system by nasal insufflation|
The compositions and methods of the disclosure particularly target the divalent metal transporter expressed on olfactory nerve terminals to transport divalent cation-coated or cation-containing nanoparticles to all regions of brain. It has been found that such divalent cation-containing nanoparticles, including those nanoparticles comprising manganese have affinity for the metal transport receptor proteins.
|Peptides that target dorsal root ganglion neurons|
The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (drg) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example.
|Non-hemolytic llo fusion proteins and methods of utilizing same|
The present invention provides recombinant proteins or peptides comprising a mutated listeriolysin o (llo) protein or fragment thereof, comprising a substitution or internal deletion of the cholesterol-binding domain or a portion thereof, fusion proteins or peptides comprising same, nucleotide molecules encoding same, and vaccine vectors comprising or encoding same. The present invention also provides methods of utilizing recombinant proteins, peptides, nucleotide molecules, and vaccine vectors of the present invention to induce an immune response to a peptide of interest..
|Recombinant proteins and their therapeutic uses|
A recombinant protein expressing one or more human growth factors, tumor antigens, and/or receptors or epitopes thereof on or within an immunogenic expression creating a recombinant protein in which one or more epitopes are presented on the surface of the sequence in their natural configuration. The growth factor, tumor antigen, and/or receptor, sequence(s) may be expressed within the encoding sequence at appropriate internal positions or at the termini as single expressions or as two or more tandem repeats..
|Fc receptor binding proteins|
This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
|Vaccine based on staphylococcal superantigen-like 3 protein (ssl3)|
The present invention relates to the field of vaccinology, especially of vaccines against staphylococcus aureus, for both human and veterinary application. In particular the invention relates to a staphylococcal superantigen-like 3 (ssl3) protein or its homolog, an immunogenic fragment of either protein, for use in a vaccine against s.
|Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same|
The present invention relates to proteins and/or fragments and derivatives thereof and their use as vaccines and in biotechnological methods. The vaccines particularly include immunogenic proteins in treponema spp.
|Novel human genes relating to respiratory diseases and obesity|
This invention relates to isolated nucleic acids comprising genes of human chromosome 12q23-qter and the proteins encoded by these genes. Expression vectors and host cells containing such genes or fragments thereof, as well as antibodies to the proteins encoded by these nucleic acids are also included herein..
|Methods for improving gut health|
The present invention provides methods for improving gut health. In particular, the invention provides methods for improving gut health by improving the digestibility of dietary proteins, decreasing the flow of protein to the lower gastrointestinal tract, and/or decreasing the levels of clostridium bacteria the upper intestinal tract of a subject.
|Virus-like particles for treatment of viral infections|
The invention provides virus-like particles for treatment of viral infections based on the virus causing the infection. The virus-like particles comprise the virus recombinant proteins that form a capsid, recombinant virus membrane proteins attached to the capsid and vrna packaged within said capsid.
|Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases|
The invention relates to the discovery of novel soluble neutral active hyaluronidase glycoproteins (shasegps), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active shasegp domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain.